April 29, 2019 06:33 AM EDT

As Praluent Q1 sales miss Wall Street expectations, FDA expands drug's label to reflect CV risk reduction

Months after sparring rivals Amgen $AMGN and partners Regeneron $REGN and Sanofi

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Pralu­ent Q1 sales miss Wall Street ex­pec­ta­tions, FDA ex­pands drug's la­bel to re­flect CV risk re­duc­tion